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doi:10.1016/j.joca.2010.12.008Despite high prevalence and social impact, osteoarthritis (OA) is far
behind other skeletal diseases like osteoporosis in the development of
disease-modifying treatments. This is mainly because little is known
about the underlying molecular mechanism that could be the thera-
peutic target. Since OA is a multifactorial disease caused by complex
interplay between environmental and genetic factors with estimates
of around 50% heritability depending on the site1, numerous efforts
and great expense have been spent on human genetic studies on OA
worldwide. Although linkage studies have shown large areas of chro-
mosomes associated with the disease, they have failed to detect the
susceptible genes. Candidate gene studies have proposed over 100
genes as being responsible; however, most of them have not later
been reproduced in larger meta-analysis studies. Recently, while
genome-wide association studies (GWAS) have led to the discovery of
over 600 gene loci in over 50 common multifactorial diseases, most
of the gene variants are of onlyminimal individual effect. Even though
the identiﬁed geneswith such small effect sizes could possibly be ther-
apeutic targets or at least prognostic markers, it is questionable
whether or not these conventional OA genetic studies are worthy of
such enormous investment. Aiming at a well-powered approach for
this highly polygenic disease with multiple risk loci conferring small
effects, consortium studies have been developed to enlarge the sample
size.Considering thediseasecharacteristics andprevalence,however, it
is ouropinion thatnotonly thequantitybut also thequalityof studies is
critical for identiﬁcation of the genetic architecture. In this sense, the
conventional OA genetic studies do not seem to us who are clinicians,
although not genetic experts, to have been performed with sufﬁcient
scientiﬁc strictness, even as compared to those on other common
diseases.
In this issue of Osteoarthritis and Cartilage, Kerkhof et al. clearly
indicate that inconsistent and ambiguous deﬁnition of OA is a crit-
ical limitation of conventional genetic studies2. In addition to the
stringency of disease deﬁnition raised by them, here we propose
two other capital issues in the conventional studies: selection of
appropriate controls and adjustment for environmental/clinical
factors, from a clinician’s point of view.Stringency of disease deﬁnition
Kerkhof et al. show that there are ﬁve different deﬁnitions of knee
OA in 28 studies involved in the Treat-OA consortium, and the deﬁni-
tions signiﬁcantly inﬂuence the prevalence and association results2.
Although most conventional genetic studies determine OA onResearch Society International. Puradiographs as Kellgren–Lawrence (KL) score¼ 2 or higher (Table I)3–7,
the KL grading is limited in reproducibility and sensitivity due to the
subjective judgment of observers and the categorical classiﬁcation
into only a ﬁve-grade scale8. In the ROAD (Research onOsteoarthritis
AgainstDisability) studywithahigh-qualitypopulation-basedcohort
database of detailed environmental and genetic information of more
than3,000participants9,wedelete themiddle and ambiguousKL¼ 2
subgroup for the case-control analysis to increase the detection
power. For example, our recent association analysis of the EPAS1
gene which was identiﬁed to be crucial for OA development in mice
was able to detect a signiﬁcant difference of the minor allelic
frequency (mAF) of a single nucleotide polymorphism (SNP) in the
gene between KL¼ 3& 4 (case;mAF¼ 11.1%) and KL¼ 0 & 1 (control;
mAF¼ 15.2%)10. The mAF of the omitted KL¼ 2 subgroup was 12.3%,
conﬁrming an inverse relationship between mAF of the SNP and KL
scores. This clearly indicates that inclusion of the KL¼ 2 subjects in
the case group had caused a decrease in the detection power. In
fact, this association was not reproduced by conventional Japanese
and Chinese studies that include KL¼ 2 in the case group11. Consid-
ering that prevalence of the KL¼ 2 subgroup is shown to be fairly
high in representative epidemiologic studies (17.3–41.3%; difference
between KL 2 and KL 3 in Table II), removal of this subgroup
may inevitably cause a decrease in the total sample size. However,
we agreewith the Kerkhof’s opinion that improvement of the deﬁni-
tion stringency may compensate a moderate decrease of the sample
size to achieve a high detection power2.
Generally, a lack of objective and quantitative measure for the
disease deﬁnition remains a fatal limitation of clinical OA studies.
The ROAD study has recently established the fully automatic
program KOACAD (knee OA computer-aided diagnosis) to quantify
the major OA parameters (joint space, osteophyte, etc.) on plain
radiographs8. We believe that the KOACAD system as well as
magnetic resonance image systems12 will serve as optimal
measures for the deﬁnition of OA in the near future, just as bone
mineral density does in osteoporosis.Selection of appropriate controls
In genetic studies on common diseases with a high prevalence,
selection of disease-free controls is essential to avoid the potential
bias due to contamination of affected subjects in the control. In
representative epidemiologic studies worldwide, the prevalence of
radiographic knee OA (KL 2) in the elderly was 30% in allblished by Elsevier Ltd. All rights reserved.
Table I
Source of subjects, deﬁnition, and adjustment for confounders in representative knee OA genetic studies
Gene GDF53 PTGS24 DVWA5 Chromosome 7q226 HLA Class II/III7
Candidate GWAS GWAS GWAS GWAS
Discovery population Case Case Case Case Case
Source (N) PBC+HP (718) HP (243); PBC (114) HP (740) PBC (698) HP (899)
Deﬁnition KL2 or CL CL; KL2 CL KL2 CL
Mean age, %female 72y, 83% NA, 100%; NA, 100% 72y, 90%; 72y, 82% NA, NA 72y, 84%
Control Control Control Control Control
PBC+HP (861) PBC (196); HS (89) HP (1,289) PBC (1,893) HP+HS (3,396)
KL1 or OR KL1 OR KL1 OD or NA
49y, 54% NA, 100%; NA, 87% 49y, 44%; 54y, 46% NA, NA 53y, 44%
Replication population Case Case Case Case Case
Source (N) HP (313) PBC (647); HP (530) HP (417); PBC (242) HP (3,142); PBC (741) HP (813); PBC(167)
Deﬁnition CL KL2; CL CL; KL2 CL, TKR; KL2 TKR; KL2
Mean age, %female 59y, 66% NA, 100%; NA, 100% 71y, 75%; 60y, 70% NA, NA; NA, NA 74y, 74%; 68y, 81%; 66y, 82%
Control Control Control Control Control
HS (485) PBC (1,712); HS (660) PBC (485); HS (413) HS (33,825); PBC (2,718); HP (294) HS (1,071); PBC (347)
NS KL1; ND KL1; NS NS; KL1 or KL¼0; NS NS; KL1 or KL¼0
57y, 65% NA, 100%; NA, 100% 68y, 63%; 56y, 74% NA, NA; NA, NA; NA, NA 66y, 64%; 68y, 39%; 60y, 65%
Adjustment Population Gender, population Population Gender, population Population
GDF5: growth differentiation factor 5, PTGS2: prostaglandin-endoperoxide synthase 2, DVWA: double von Willebrand factor A domains, HLA: human leukocyte antigen.
PBC: population-based cohort, HP: hospital patients, HS: healthy subjects, CL: clinical diagnosis, TKR: total knee replacement, OR: orthopaedic disease or injury, OD: other
disease than OA, ND: not diagnosed for OA, NS: no sign of OA, NA: not available.
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and China (Shanghai) (Table II)13. Furthermore, the prevalence of
asymptomatic knee OA was 24–36% in all populations. Hence, if
so-called healthy subjects without knee symptoms were collected
as controls, a considerable numberof OA subjectswould be included
in the control group. Even in a series of genetic studies in Japanwith
a high OA prevalence13, the control subjects are miscellaneous
mixtures of various populations including considerable numbers
of so-called healthy subjects and other disease patients without
radiographic diagnosis (Table I)3,5,7, indicating that a substantial
percentage in the control groups are affected subjects. A recent anal-
ysis of the effect of controls selected with different levels of strin-
gency on the association of known knee OA susceptibility genes
demonstrates that a controlwith poor selection orwithout selection
cannot be compensated by increase of the sample size14. Hence,
selection of appropriate controls conﬁrmed to be disease-free may
be crucial to achieve a high detection power.
Adjustment for confounding environmental/clinical factors
Lastly, we should again note that OA is a multifactorial disease
with environmental and genetic backgrounds and that the genetic
contribution is less than half in knee OA1. A recent report by
Takahashi et al. constructed knee OA prediction models based on
genotype (combination of three risk alleles of asporin, GDF5 and
DVWA) and environmental/clinical information (age, gender andTable II
Prevalence of radiographic knee OA in representative population-based cohorts
Cohort ROAD Framingham Zoetermeer Jo
Ethnicity Japan White in USA Netherlands Bl
Age 60 63 60 
Total number 2,282 1,420 1,123 1,
Radiographic knee OA (%)
KL 2 61.9 33.0 30.0 40
KL 2 (symptomatic) 26.1 9.5 13
KL 2 (asymptomatic) 35.8 23.5 27
KL 3 20.6 15.7 10.2 13
KL 2 (asymptomatic) was deﬁned as KL 2 (radiographic) but KL 2 (symptomatic).
References: Osteoarthritis Cartilage 2009;17:1137 (ROAD). Arthritis Rheum 1987;30:914
J Rheumatol 2007;34:172 (Johnston County). Arthritis Rheum 2001;44:2065 (Beijing). R
J Rheumatol 2006;33:2271 (NHANES III).body mass index), and evaluated the predictive power by area
under the curve (AUC; range, 0.5 [worst] to 1 [best]) on a receiver
operating characteristic (ROC) curve in a case-control association
study15. The result was that the power by the genotype informa-
tion was very small (AUC¼ 0.554), implicating uselessness of the
three famous genotypes as a prognostic marker. Contrarily, the
environmental/clinical information was a much better predictor
(AUC¼ 0.678), but was little improved by the combination with
the genotype information (AUC¼ 0.685), again conﬁrming its
uselessness. Hence, to achieve a high detection power for the
susceptibility gene, all efforts should be made to exclude the inﬂu-
ence of environmental/clinical factors. Surprisingly, however, there
are big differences in age and gender between case and control
groups in previous representative studies (Table I). Even a sole
difference in age of about 20 years between case and control
groups that is seen in the Japanese studies3,5,7 is calculated to
cause an increase of odds ratio for OA to 2.65 (¼1.0520), according
to the authors’ own estimation (1.05/year)15. Indeed, we are not
opposed to recent activities of OA consortiums to pool subjects
worldwide; however, we should note that the pooled subjects
are miscellaneous mixtures of various populations with different
backgrounds. Selection of case and control subjects with similar
backgrounds is essential to minimize selection bias which strongly
inﬂuences the results in genetic studies with small effect sizes of
the risk alleles. Hence, at least for the initial screening, case and
control groups should be selected from a single population-basedhnston county Beijing Shanghai NHANES III
ack & whites in USA China China Black & whites in USA
65 60 60–69 60
175 1,781 700 2,415
.6 38.8 64.1 37.4
.6 12.0 12.1
.0 26.8 25.3
.6 10.2
NHANES: National Health and Nutrition Examination Survey.
(Framingham). Ann Rheum Dis 1989;48:271 (Zoetermeer).
heumatol Int 2005;25:585 (Shanghai).
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ing environmental/clinical factors which have been identiﬁed in
preparatory epidemiologic analysis in the cohort. The reproduc-
ibility may then be examined in other replication cohorts of the
worldwide consortiums, after adjustment for the speciﬁc con-
founding factors in the respective cohorts.
Taken together, conventional OA genetic studies appear to
compare a case group containing a substantial number of subjects
with ambiguous deﬁnition vs a control group containing a substan-
tial number of affected subjects, plus without adjustment for con-
founding environmental/clinical factors. Contrary to the genetic
studies, studies of clinical trial and observational epidemiology
are performed under a sound scientiﬁc rigidity in compliance
with very strict rules to examine the accurate effect sizes of inter-
ventions and environmental/clinical factors, respectively. Although
genetic studies also examine the effect sizes of genes, they seem to
have their ﬂing in the lawless zone. Introduction of strict regulation
in the genetic ﬁeld, just like Consolidated Standards of Reporting
Trials (CONSORT) guidelines in the clinical trial ﬁeld16, might
improve the scientiﬁc rigidity. Otherwise, genetic studies seem to
be unable to reach a genuine therapeutic target or even a prognostic
marker of OA despite numerous efforts and great expense.
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